Exelixis, Inc. (NASDAQ:EXEL) has released their financials results for the 4Q2016 and FY2016. The company also provided an update on its corporate objectives and upcoming milestones. For its 4Q2016, EXEL recorded a net income of $35.1 million, as compared to a net loss for 4Q2015. Exelixis was able to...
Before we go into details of Delcath Systems, Inc. (NASDAQ:DCTH), a biotech company that needs your immediate attention is OncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP). OBMP is a clinical stage biopharmaceutical company that develops cancer immunotherapy products. The company has proprietary rights to a breast and prostate patent vaccine; and a process...
Array Biopharma Inc (NASDAQ:ARRY) a biopharmaceutical firm focused on the development, commercialization and discovery of targeted small molecule cancer treatments reported financial results for 2Q2017 and released an update on the development of its major clinical development plans. Ron Squarer, the CEO, reported that they are delighted to announce that...
In the last trading session, the stock price of Novavax, Inc. (NASDAQ:NVAX) gained over 14% to close the session at $1.62 on more than normal volume. No specific news accounts for this move. Last month, it commenced a Phase II clinical study evaluating the immunogenicity and safety of its...
Shares of (NASDAQ:) are currently up by more than from the open today and are trading at $. More than shares have exchanged hands compared to an average trading volume of . At the current pps, the market cap stands at $. The stock prices of...
Shares of (NASDAQ:) are currently up by more than from the open today and are trading at $. More than shares have exchanged hands compared to an average trading volume of . At the current pps, the market cap stands at $. The stock prices of...
Shares of (NASDAQ:) are currently up by more than from the open today and are trading at $. More than shares have exchanged hands compared to an average trading volume of . At the current pps, the market cap stands at $. The stock prices of...
Gilead Sciences, Inc. (NASDAQ:GILD) hasn’t been able to bring a smile on the investors’ faces throughout the first three quarters of 2016, and in the last quarter as well, the company did not break the ice. Following the downward trend, the company announced its Q4 2016 results recently, and...
Galena Biopharma Inc (NASDAQ:GALE) a biopharmaceutical firm committed to the advancement and commercialization of hematology as well as oncology therapeutics issued the report from a meeting of the DSMB for the two IST combination clinical studies with NeuVax™ plus trastuzumab. The studies are being carried out in breast cancer...
The stock price of Conatus Pharmaceuticals Inc (NASDAQ:CNAT) are moving north on the chart since last few days. Recent NASH play has finally rewarded firm’s shareholders. The biotech concern has made a transformational collaboration agreement with drug giant company Novartis AG (ADR)(NYSE:NVS) about its compound emricasan. The biotech industry continues...

Subscribe to our mailing list

* indicates required

Create a future where the human body can repair, restore, and rejuvenate itself

 

Trading Symbol

OTC: PLSI

The Next Big Global Cannabis Play